Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

Abstract Background Biomarkers may contribute to improved cardiovascular risk estimation. Glycated hemoglobin A1c (HbA1c) is used to monitor the quality of diabetes treatment. Its strength of association with cardiovascular outcomes in the general population remains uncertain. This study aims to ass...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christoph Sinning, Nataliya Makarova, Henry Völzke, Renate B. Schnabel, Francisco Ojeda, Marcus Dörr, Stephan B. Felix, Wolfgang Koenig, Annette Peters, Wolfgang Rathmann, Ben Schöttker, Hermann Brenner, Giovanni Veronesi, Giancarlo Cesana, Paolo Brambilla, Tarja Palosaari, Kari Kuulasmaa, Inger Njølstad, Ellisiv Bøgeberg Mathiesen, Tom Wilsgaard, Stefan Blankenberg, Stefan Söderberg, Marco M. Ferrario, Barbara Thorand
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Biomarkers Glycated hemoglobin A1c (HbA1c) Cardiovascular risk Mortality BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) MORGAM (MONICA Risk Genetics Archiving and Monograph) Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/9731035e63df4338aefbcedd86a46c91
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium

Ejemplares similares